Expert Opinion on Drug Safety [ISSN 1474-0338]; [e- ISSN 1744-764X] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles on all aspects of drug safety, as well as original papers on the clinical implications of drug treatment safety issues.
Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.
Expert Opinion on Drug Safety aims to address the needs of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.
The journal welcomes:
- Reviews covering occurrence, management and prevention of drug-associated adverse events
- Reviews covering risk-benefit analyses of individual drugs and drug classes
- Reviews covering safety in 'at-risk' patient populations
- Reviews covering comparative tolerability studies
- Reviews covering pharmacovigilance and pharmacoepidemiological studies
- Drug safety evaluations reviewing the safety data on a specific drug
- Original research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes
- Original research papers on methods for the detection and evaluation of drug-associated adverse events
Please note that the journal does not publish case reports or animal studies. Letters to the Editor should discuss articles previously published in the journal.
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results.
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Drug Safety, part of the Expert Collection brand.
Authors can publish gold open access in this journal and may choose to publish using our Accelerated Publication services.
Read the Instructions for Authors for information on how to submit your article. For any pre-submission enquiries, please contact the Commissioning Editor.
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110803/Subject-Sample-2021-Bioscience.jpg"})